Eli Lilly (NYSE: LLY) to Announce Q4 2025 Financial Results on February 4, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy LLY?
Source: Newsfilter
- Earnings Announcement: Eli Lilly is set to release its fourth-quarter 2025 financial results on February 4, 2026, which is expected to provide investors with critical financial data to assess the company's performance.
- Conference Call Details: On the same day, Lilly will conduct a conference call at 10 a.m. Eastern Time to elaborate on its financial performance, enhancing communication with investors and the media.
- Live Webcast Access: Investors and the general public can access the live webcast of the conference call through a link on Lilly's website, ensuring transparency and broadening audience reach to enhance the company's image.
- Commitment to Diversity: Lilly is dedicated to reflecting global diversity through innovative clinical trials, advancing drug development to tackle significant health challenges worldwide, thereby reinforcing its leadership position in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 874.000
Low
950.00
Averages
1192
High
1500
Current: 874.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Expected to Report Strong Q1 Earnings Growth
- Earnings Expectations: Eli Lilly is projected to report Q1 EPS of $6.85 with a 40.3% year-over-year revenue increase to $17.86 billion, indicating strong performance in the obesity treatment market that could drive stock price up.
- Drug Catalysts: Analysts believe that obesity drugs Mounjaro and Zepbound will anchor Lilly's medium-term growth, while the approval of Foundayo and the $7 billion acquisition of Kelonia Therapeutics serve as near-term catalysts that may enhance market confidence.
- Management Guidance: Analyst Stephen Ayers is keenly awaiting management's reaffirmation of the 2026 revenue guidance, as maintaining the current outlook may signal strong market performance for Foundayo, whereas a revision to the lower end could indicate pricing erosion or lagging uptake.
- Market Dynamics: Despite a more than 17% decline in Eli Lilly's stock this year, the company has beaten EPS and revenue estimates 100% of the time over the past two years, maintaining a positive outlook for future performance.
See More
Eli Lilly's Foundayo Launch Insights Awaited Amid Sales Uncertainty
- Launch Delays: Eli Lilly's weight-loss pill Foundayo launched in the U.S. in early April, but its absence from first-quarter financials leaves investors uncertain about its market performance, with analysts suggesting initial sales may lag behind Novo Nordisk's Wegovy.
- Insufficient Sales Data: Investors generally believe that 5 to 6 weeks of prescription data are needed to accurately assess Foundayo's sales trajectory, with BMO Capital Markets analysts noting that CEO Dave Ricks' comments will be crucial, highlighting the market's focus on the new drug.
- International Market Pressure: While Lilly's Mounjaro saw sales double in India, the introduction of cheaper generic versions of Novo's Wegovy by local manufacturers is expected to pressure demand, particularly as the mix of pricing and demand for these drugs in global markets becomes a focal point for investors.
- Policy Uncertainty: The uncertainty surrounding U.S. reimbursement policies for obesity drugs has heightened investor concerns, especially following the delay of the Medicare pilot program, which may impact Lilly's pricing strategies and market share in the lucrative U.S. market.
See More
Hims CEO's Pay Gap Sparks Attention Ahead of Vote
- Compensation Structure Analysis: Hims CEO Andrew Dudum's compensation of $22.96 million, down 7% from last year, remains 272 times the median employee pay, highlighting a significant pay gap that may impact the company's governance image.
- Performance Target Achievement: Hims met 94% of its revenue target and 98% of its adjusted EBITDA target last year, resulting in executives receiving 93.72% of their annual incentive bonuses, reflecting stable performance in the highly competitive GLP-1 weight-loss market.
- Stock Award Details: Dudum received 306,406 restricted stock units (RSUs) and performance-based stock options, with options convertible into 278,622 shares at minimum performance and up to 1.39 million shares at maximum performance, indicating the company's focus on long-term incentives.
- Intensifying Market Competition: Hims faces increasing competition in the GLP-1 market from Amazon and other digital platforms, recently expanding access to branded treatments from Novo Nordisk and Eli Lilly to enhance market share and address regulatory pressures.
See More
The Future of AI in Healthcare Applications
- AI in Health Management: Alex Zhavoronkov, founder of Insilico Medicine, advocates for increased consumer use of AI to answer basic health questions like dietary advice, which can save time with doctors and enhance health management efficiency.
- Innovative Health Tools: OpenAI's ChatGPT Health and Amazon's Health AI tools aim to provide data-driven health advice by securely connecting medical records and wellness apps, although these tools are not intended for diagnosis or treatment.
- Accelerated Drug Development: Zhavoronkov notes that AI tools reduce the drug development candidate stage to 18 months, significantly improving efficiency compared to the traditional four years, highlighting AI's immense potential in the pharmaceutical industry.
- Importance of Human Collaboration: Shreehas Tambe from Biocon emphasizes the necessity of
See More
The Future of AI in Healthcare Applications
- AI Health Q&A: Alex Zhavoronkov, CEO of Insilico Medicine, emphasizes that AI can answer basic health questions like dietary advice, thereby saving time spent with doctors and enhancing consumer health management efficiency.
- New Tool Launches: OpenAI and Amazon launched health tools in January, with ChatGPT Health allowing secure connections to medical records, while Amazon's HealthAI provides advice based on medical records and lab results, advancing AI applications in consumer healthcare.
- Reduced R&D Time: Zhavoronkov noted that AI tools cut drug development time to 18 months, significantly improving efficiency compared to the traditional four years, which has crucial strategic implications for the pharmaceutical industry.
- Importance of Human Oversight: Shreehas Tambe, CEO of Biocon, stresses the need for AI models to be validated by professionals to ensure their effectiveness in drug discovery, avoiding erroneous results due to users' unfamiliarity with the technology.
See More
Eli Lilly's Dominance in Weight-Loss Drug Market
- Market Leadership: Eli Lilly's dominance in the weight-loss drug market positions it well for future growth, with projections indicating significant expansion over the next decade, although some investors remain skeptical about its ability to deliver superior returns in the next five years.
- Analyst Optimism: Morgan Stanley analyst Terence Flynn reiterated a 'buy' rating on Eli Lilly stock with a price target of $1,327, suggesting a potential upside of about 52% from the current price of $870, which could push the company's market cap above $1 trillion if achieved.
- Sales Potential: Flynn anticipates that Eli Lilly's newly launched weight-loss pill Foundayo, combined with Zepbound, could generate approximately $31 billion in U.S. sales next year, with projections rising to $45 billion by 2030, indicating robust revenue growth potential.
- Competition and Risks: Despite CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, Eli Lilly faces increasing competition; however, its strong pipeline in weight-loss drugs and diversification strategy should help maintain its market leadership.
See More
Eli Lilly Expected to Report Strong Q1 Earnings Growth
- Earnings Expectations: Eli Lilly is projected to report Q1 EPS of $6.85 with a 40.3% year-over-year revenue increase to $17.86 billion, indicating strong performance in the obesity treatment market that could drive stock price up.
- Drug Catalysts: Analysts believe that obesity drugs Mounjaro and Zepbound will anchor Lilly's medium-term growth, while the approval of Foundayo and the $7 billion acquisition of Kelonia Therapeutics serve as near-term catalysts that may enhance market confidence.
- Management Guidance: Analyst Stephen Ayers is keenly awaiting management's reaffirmation of the 2026 revenue guidance, as maintaining the current outlook may signal strong market performance for Foundayo, whereas a revision to the lower end could indicate pricing erosion or lagging uptake.
- Market Dynamics: Despite a more than 17% decline in Eli Lilly's stock this year, the company has beaten EPS and revenue estimates 100% of the time over the past two years, maintaining a positive outlook for future performance.
See More
Eli Lilly's Foundayo Launch Insights Awaited Amid Sales Uncertainty
- Launch Delays: Eli Lilly's weight-loss pill Foundayo launched in the U.S. in early April, but its absence from first-quarter financials leaves investors uncertain about its market performance, with analysts suggesting initial sales may lag behind Novo Nordisk's Wegovy.
- Insufficient Sales Data: Investors generally believe that 5 to 6 weeks of prescription data are needed to accurately assess Foundayo's sales trajectory, with BMO Capital Markets analysts noting that CEO Dave Ricks' comments will be crucial, highlighting the market's focus on the new drug.
- International Market Pressure: While Lilly's Mounjaro saw sales double in India, the introduction of cheaper generic versions of Novo's Wegovy by local manufacturers is expected to pressure demand, particularly as the mix of pricing and demand for these drugs in global markets becomes a focal point for investors.
- Policy Uncertainty: The uncertainty surrounding U.S. reimbursement policies for obesity drugs has heightened investor concerns, especially following the delay of the Medicare pilot program, which may impact Lilly's pricing strategies and market share in the lucrative U.S. market.
See More
Hims CEO's Pay Gap Sparks Attention Ahead of Vote
- Compensation Structure Analysis: Hims CEO Andrew Dudum's compensation of $22.96 million, down 7% from last year, remains 272 times the median employee pay, highlighting a significant pay gap that may impact the company's governance image.
- Performance Target Achievement: Hims met 94% of its revenue target and 98% of its adjusted EBITDA target last year, resulting in executives receiving 93.72% of their annual incentive bonuses, reflecting stable performance in the highly competitive GLP-1 weight-loss market.
- Stock Award Details: Dudum received 306,406 restricted stock units (RSUs) and performance-based stock options, with options convertible into 278,622 shares at minimum performance and up to 1.39 million shares at maximum performance, indicating the company's focus on long-term incentives.
- Intensifying Market Competition: Hims faces increasing competition in the GLP-1 market from Amazon and other digital platforms, recently expanding access to branded treatments from Novo Nordisk and Eli Lilly to enhance market share and address regulatory pressures.
See More
The Future of AI in Healthcare Applications
- AI in Health Management: Alex Zhavoronkov, founder of Insilico Medicine, advocates for increased consumer use of AI to answer basic health questions like dietary advice, which can save time with doctors and enhance health management efficiency.
- Innovative Health Tools: OpenAI's ChatGPT Health and Amazon's Health AI tools aim to provide data-driven health advice by securely connecting medical records and wellness apps, although these tools are not intended for diagnosis or treatment.
- Accelerated Drug Development: Zhavoronkov notes that AI tools reduce the drug development candidate stage to 18 months, significantly improving efficiency compared to the traditional four years, highlighting AI's immense potential in the pharmaceutical industry.
- Importance of Human Collaboration: Shreehas Tambe from Biocon emphasizes the necessity of
See More
The Future of AI in Healthcare Applications
- AI Health Q&A: Alex Zhavoronkov, CEO of Insilico Medicine, emphasizes that AI can answer basic health questions like dietary advice, thereby saving time spent with doctors and enhancing consumer health management efficiency.
- New Tool Launches: OpenAI and Amazon launched health tools in January, with ChatGPT Health allowing secure connections to medical records, while Amazon's HealthAI provides advice based on medical records and lab results, advancing AI applications in consumer healthcare.
- Reduced R&D Time: Zhavoronkov noted that AI tools cut drug development time to 18 months, significantly improving efficiency compared to the traditional four years, which has crucial strategic implications for the pharmaceutical industry.
- Importance of Human Oversight: Shreehas Tambe, CEO of Biocon, stresses the need for AI models to be validated by professionals to ensure their effectiveness in drug discovery, avoiding erroneous results due to users' unfamiliarity with the technology.
See More
Eli Lilly's Dominance in Weight-Loss Drug Market
- Market Leadership: Eli Lilly's dominance in the weight-loss drug market positions it well for future growth, with projections indicating significant expansion over the next decade, although some investors remain skeptical about its ability to deliver superior returns in the next five years.
- Analyst Optimism: Morgan Stanley analyst Terence Flynn reiterated a 'buy' rating on Eli Lilly stock with a price target of $1,327, suggesting a potential upside of about 52% from the current price of $870, which could push the company's market cap above $1 trillion if achieved.
- Sales Potential: Flynn anticipates that Eli Lilly's newly launched weight-loss pill Foundayo, combined with Zepbound, could generate approximately $31 billion in U.S. sales next year, with projections rising to $45 billion by 2030, indicating robust revenue growth potential.
- Competition and Risks: Despite CVS Health's decision to drop coverage for Zepbound in favor of the cheaper Wegovy, Eli Lilly faces increasing competition; however, its strong pipeline in weight-loss drugs and diversification strategy should help maintain its market leadership.
See More
